Open Access Repository

Effect of a Fucoidan Extract on Insulin Resistance and Cardiometabolic Markers in Obese, Nondiabetic Subjects: A Randomized, Controlled Trial

Wright, CM, Bezabhe, W ORCID: 0000-0002-3028-6949, Fitton, JH, Stringer, DN, Bereznicki, LRE ORCID: 0000-0003-3974-3437 and Peterson, GM ORCID: 0000-0002-6764-3882 2018 , 'Effect of a Fucoidan Extract on Insulin Resistance and Cardiometabolic Markers in Obese, Nondiabetic Subjects: A Randomized, Controlled Trial' , Journal of alternative and complementary medicine , pp. 1-7 , doi: 10.1089/acm.2018.0189.

Full text not available from this repository.

Abstract

Objectives: To determine whether a fucoidan extract reduced insulin resistance and/or altered other cardiometabolic markers in an obese, nondiabetic population.Design: Single-site, double-blinded, placebo-controlled, randomized controlled trial.Setting/Location: Hobart, Tasmania, Australia.Subjects: Eligible subjects were obese, with no history of diabetes, and ages between 18 and 65 years.Interventions: Subjects were randomly assigned, in even blocks of 10, to either active fucoidan 500 mg orplacebo capsules twice daily for 90 days, with identical measurements performed at baseline and follow-up.Outcome measures: The primary outcome was insulin resistance, defined by the homeostasis model ofassessment (HOMA) values. Secondary outcomes were lipid profile, glycosylated hemoglobin, urea electrolytesand creatinine, liver function tests, full/complete blood count, fasting insulin, fasting glucose, quantitativeinsulin sensitivity check index, glucose area under the curve, weight, body mass index, waist circumference,and systolic and diastolic blood pressure. The trial was registered with the Australian New Zealand ClinicalTrial Registry (ACTRN12614000495628) and the Therapeutic Goods Administration (2014/0348), and wasfunded by Marinova Pty. Ltd.Results: There were no differences in the 90-day outcome measures between placebo and active treatment inthe intention-to-treat-analysis (n = 35 for active, n = 37 for placebo). The mean change in HOMA scores was 0for the placebo and -0.1 for the active groups ( p = 0.73). Self-reported adherence was high, consistent withcapsule counting at the conclusion of the trial.Conclusions: Fucoidan taken twice daily for a period of 90 days did not markedly affect insulin resistance orother measured parameters of cardiometabolic health in an obese, nondiabetic cohort. This could be due to anintrinsic lack of efficacy, lower than measured adherence, or because longer therapy and/or higher baselineinsulin resistance are required to exert a significant effect.

Item Type: Article
Authors/Creators:Wright, CM and Bezabhe, W and Fitton, JH and Stringer, DN and Bereznicki, LRE and Peterson, GM
Keywords: fucoidan, obesity, prediabetes, glucose tolerance, Fucus vesiculosus
Journal or Publication Title: Journal of alternative and complementary medicine
Publisher: Mary Ann Liebert Inc Publ
ISSN: 1075-5535
DOI / ID Number: 10.1089/acm.2018.0189
Copyright Information:

Copyright 2018 Mary Ann Liebert, Inc.

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP